Prostate Cancer Diagnostics

Recently released analysis of ¹⁸F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.

NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.

Salvage radiotherapy decisions for patients with recurrent prostate cancer after prostatectomy change after ¹⁸F-fluciclovine PET/CT reveals higher positive findings than conventional imaging.

Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.

Recently released study results indicate whole-body MRI is superior to bone scan for prognosis in patients with metastatic hormone-naïve prostate cancer.

The recent release of EMPIRE-1 phase 2/3 trial results indicates the use of fluorine 18 fluciclovine PET/CT to guide salvage postprostatectomy radiotherapy increases event-free survival from biochemical recurrence or persistence.

Promising diagnostic and prognostic information with PSMA-based radioligands discussed in recently released review article.

Investigators released participant group data from a clinical trial looking at the use of fluorine 18 fluciclovine PET/CT in men with prostate cancer and biochemical recurrence to identify potential targets for therapy.

Updates on patient eligibility and methods from the INDICATE phase 3 trial were presented at the 2021 American Society of Clinical Oncology annual meeting.

Real-world study suggests prostate-specific antigen levels, race, and the use of androgen deprivation therapy are predictors of a positive FACBC PET/CT scan.